In animal models, it was found that FABP4 inhibitors ameliorate insulin resistance, diabetes mellitus, fatty liver disease, and atherosclerosis, implying that inhibition of FABP4 may be a therapeutic strategy for metabolic syndrome [49]. This evidence concerns the gene FABP4 and metabolic syndrome.